Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE)/b) shared a CEO transition and strategic update. Effective June 30, 2026, Mike McCormick becomes CEO while John Erb remains Chairman. In Q1 2026, revenue grew and gross margin reached 70.1%, a 14-point improvement.
About 75% of revenue comes from pediatric and critical care. Priorities include expanding Aquadex pediatric indications down to 5 kg, integrating the acquired Rendiatech kidney monitoring technology, strengthening capital, reducing cash burn, and targeting consistent double-digit revenue growth and continued margin expansion.
Positive
- Q1 2026 revenue increased 26% year-over-year
- Q1 2026 gross margin improved to 70.1%, up 14 percentage points
- Approximately 75% of revenue from pediatric and critical care customers with ongoing adoption
- Acquisition of Rendiatech adds automated kidney function monitoring to the portfolio
- Strengthened capital position to support commercial and development initiatives
- Explicit objectives for consistent double-digit revenue growth and further margin expansion
Negative
- Company highlights ongoing cash burn and the need to meaningfully reduce it through 2026
News Market Reaction – NUWE
In the Jun 24 session, NUWE declined 30.47%, reflecting a significant negative market reaction. Argus tracked a trough of -33.9% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 18 | Education initiative | Positive | -1.6% | Aquadex training for over 280 physicians at critical care education summit. |
| Jun 16 | Leadership change | Positive | -0.9% | Appointment of Mike McCormick as CEO with John Erb remaining chairman. |
| Jun 10 | Collaboration expansion | Positive | +4.7% | Expanded Aquadex installs and FDA pre-submission on lowering pediatric weight limit. |
| Jun 08 | Offering closing | Negative | -1.0% | Closing of $6.0M registered offering with shares and multiple warrant series. |
| Jun 05 | Offering pricing | Negative | -61.2% | Pricing of $6M public offering at $0.30 with large warrant overhang. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock has generally tracked news tone, with mostly aligned reactions but some selling on positive headlines.
Key Terms
reverse stock split financial
pre-funded warrants financial
going concern financial
material weaknesses in internal control over financial reporting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick.
Dear Valued Shareholders,
Recently we announced an important leadership transition for Nuwellis. Effective June 30, 2026, I will assume the role of Chief Executive Officer, while John Erb will transition from his executive responsibilities and continue as Chairman of the Board.
We embark on this leadership transition with growing commercial momentum, improving margins, and a strengthened capital position. During the first quarter of 2026, Nuwellis delivered
At the same time, we have taken meaningful steps to improve operating efficiency and reduce capital requirements. By concentrating resources on our highest-priority opportunities and aligning spending with near-term growth initiatives, we believe we are building a stronger foundation for sustainable value creation.
Looking forward, our strategy remains focused on the areas where we see the greatest opportunity to expand our impact and strengthen our business.
Today, approximately
In pediatrics, we continue advancing our efforts to expand the Aquadex indication from the current 20-kilogram patient population to children weighing as few as 5 kilograms and above. As part of this initiative, we recently engaged with the FDA regarding a proposed submission strategy that includes the use of existing clinical experience and real-world clinical evidence generated through pediatric use of Aquadex. We believe this effort has the potential to expand access to the therapy for a broader group of pediatric patients while further strengthening our position in this important market.
We are also advancing our cardiorenal platform beyond fluid removal. Earlier this year, Nuwellis acquired Rendiatech, Inc., adding automated kidney function monitoring technology to our portfolio. This acquisition expands our presence in the ICU by complementing the Aquadex platform with diagnostic monitoring capabilities, creating additional opportunities for growth within our existing customer base and the broader critical care market.
We recently strengthened our capital position, providing resources to execute on our key commercial and development initiatives. Maintaining our Nasdaq listing remains an important component of our strategy as we continue to broaden awareness of Nuwellis among institutional and long-term investors. Our focus continues to be on disciplined deployment of capital toward opportunities that can accelerate growth, expand margins, and create long-term shareholder value.
Furthermore, improving operational efficiency and reducing cash burn remains a key priority as we move through 2026. Through disciplined expense management and a continued focus on our highest-impact growth initiatives, we are working toward a meaningful reduction in burn from the first quarter through year-end while continuing to invest in opportunities that drive long-term value creation.
As we enter the next phase of growth, our objectives are clear:
- Deliver consistent double-digit revenue growth through focused commercial execution
- Continue expanding gross margins through product mix, operational efficiency, and increased utilization
- Advance strategic pipeline programs that complement our existing critical care and pediatric franchise
- Maintain disciplined capital allocation while pursuing opportunities that create long-term shareholder value
We are grateful to our employees, customers, clinicians, investors, and Board members for their continued support and confidence. We believe Nuwellis is well positioned to build upon its recent momentum and execute on the significant opportunities ahead in critical care, pediatrics, and cardiorenal medicine.
Thank you for your continued support.
Sincerely,
Mike McCormick
Incoming Chief Executive Officer
John Erb
Chairman of the Board
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Media Contact:
CORE PR
media@nuwellis.com
